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Objective. Evaluate in postmenopausal women the eﬀect of red clover extract (RCE) isoﬂavones over subjective status of skin,
appendages, and several mucosal sites. Method.P o s t m e n o p a u s a lw o m e n( n = 109) were randomly assigned to receive either two
daily capsules of the active compound (80mg RCE, Group A) or placebo of equal appearance (Group B) for a 90-day period.
After a washout period of 7 days, medication was crossed over and taken for 90 days more. Subjective improvement of skin,
appendages, and several mucosal site status was assessed for each studied group at 90 and 187 days using a visual analogue scale
(VAS). In addition, libido, tiredness, and urinary, sleep, and mood complaints were also evaluated. Results.W o m e na f t e rR C E
intervention(bothgroups)reportedbettersubjectiveimprovementofscalphairandskinstatus,libido,mood,sleep,andtiredness.
Improvement of urinary complaints, nail, body hair, and mucosa (oral, nasal, and ocular) status did not diﬀer between treatment
phases (intra- and intergroup). Overall satisfaction with treatment was reported higher after RCE intervention (both groups) as
compared to placebo. Conclusion. RCE supplementation exerted a subject improvement of scalp hair and skin status as well as
libido, mood, sleep, and tiredness in postmenopausal women.
1.Introduction
As a result of increased life expectancy, nowadays, women
spend more than one third of their lives in a state of estrogen
deprivation which in turn leads to a number of signiﬁcant
long-term changes [1]. Indeed, two out of three women in
the menopausal transition present diﬀerent complaints [2].
Increased osteoporosis and cardiovascular risk, vasomotor
episodes, and sleep disturbances have been the main research
topics and focus of treatment. Others aspects such as urinary
complaints, loss of libido, and changes in hair, nail, skin,
or mucosal status have often been disregarded (neglected)
by researchers and health care providers but not by women
themselves.
Hormone therapy (HT), using diﬀerent estrogenic com-
pounds, has shown its eﬀectiveness over a number of
these complaints; nevertheless, current HT use has become
controversial due to suspected increased risk of breast
cancer and cardiovascular disease [3]. Furthermore, 10% of
western women display conditions that contraindicate HT
use: history of estrogen-dependent malignancy, liver disease,
thromboembolic disorders, and severe migraine [4]. Under
this scenario, the use of alternatives to HT such as botanical
and dietary supplements (i.e., phytoestrogens) has increased
for the management of menopausal complaints [2]. Beside
coumestrols and ﬂavonoids, isoﬂavonoids are the main
active substances of “phytoestrogens” [5]. Epidemiological
and clinical research has shown the positive eﬀects of soy
isoﬂavone consumption over bone [6–8] and the risk of
developing several female cancers [9–14]. Reports indicate
that isoﬂavones exhibit estrogenic activity through the
activationofestrogenreceptors(ERs)andalsoantiestrogenic2 Obstetrics and Gynecology International
activity by competitive binding to the ER and estradiol (E2)
inhibition. Moreover, they have a signiﬁcantly higher aﬃnity
for the ER-beta than ER-alpha [15].
Trifolium pratense or red clover (RC) is a perennial herb
growing in all temperate and subtropical areas around the
world. In several cultures, it is used as traditional medicine
[16]. Besides its daidzein and genistein content, unlike
soy, RC displays a high content of methylized precursors:
biochanin A and formononetin [5]. After several years of
clinical research with RC, there is evidence supporting their
positive eﬀects in climacteric women in terms of vasomotor
symptoms [17], bone mineral density [18], mood [19],
vaginal and sexual health [20, 21], and serum lipids [22].
Despitethis,RCdataonskin,appendages,includingmucosal
sites, are scarce or lacking. Hence, the aim of the present
paper was to evaluate in postmenopausal women the eﬀect
of red clover extract (RCE) isoﬂavones over subjective status
of skin, appendages, and several mucosal sites. In addition,
libido, tiredness, and urinary, sleep, and mood complaints
were also evaluated.
2. Methods
2.1. Study Design and Participants. A prospective random-
ized, double-blind, placebo-controlled trial was carried out
from May 2003 to November 2004 at the Study Center Med
XIX and the Department of Gynecological Endocrinology
and Reproductive Medicine, General Hospital of the Medical
University of Vienna, Vienna, Austria. Study protocol was
approved by the Ethics Committee of the above-mentioned
university and aimed at evaluating the eﬀect of red clover
isoﬂavonesupplementationinpostmenopausalwomen,with
several proposed targets: vasomotor and general menopausal
symptoms, selected sex hormones and endometrium [1],
and depressive/anxiety symptoms [19]. The present paper
speciﬁcally presents data on the eﬀect of RCE over subject
skin, appendages, and mucosal status in addition to libido,
tiredness and urinary, sleep, and mood complaints.
Postmenopausal women (amenorrhea >12 months), 40
years or older with moderate-to-severe menopausal symp-
toms (Kupperman index ≥15) were recruited from the daily
routine of the Menopause Ambulance of the General Hospi-
tal and the Study Center Med XIX as previously described
[1]. Those with a positive pregnancy test, nonwillingness
to adhere to the control dates and take the prescribed
preparations, on hormonal therapy (HT), or with known
isoﬂavone hypersensitivity were excluded. A baseline FSH
>35mlU/mL was conﬁrmatory of postmenopausal status
[1].
After being informed about the research (aims and
method) and providing written consent, participants were
randomly assigned to receive either two capsules of the active
RCE compound (80mg red clover isoﬂavones, Group A) or
placebo of equal appearance (Group B) for a 90-day period.
After a 7-day washout period, subjects switched to receive
the opposite treatment for another 90 days. Additional
examinations comprised anamnesis, medication anamnesis,
and height, weight, and blood pressure determinations
at proposed intervals [1]. Body mass index (BMI) was
calculated as weight (kg)/squared height (m) [20].
2.2. Assessment of Studied Parameters. Studied variables
related to subjective skin, appendages, and mucosal status
and libido, tiredness, and urinary, sleep, and mood com-
plaints were measured for each studied group at 90 and 187
days using a visual analog scale (VAS) scored from 0 to 100.
Scores were indicative of subjective percent improvement of
the symptom or condition.
2.3. Preparations. RCE capsules contained a standardized
content of 40mg aglyconic isoﬂavones in form of biochanin
A, formononetin, genistein, and daidzein. RCE and placebo
capsules (90mg lactose) were of identical design, packed
in opaque containers, labeled as A or B, and blinded to
investigators and participants until the end of the trial after
which the code was broken.
2.4. Statistical Analysis. Statistical analysis was performed
on an intention-to-treat basis using SPSS software package
(Version 19.0 for Windows, SPSS Inc., Chicago, Ill, USA).
Data are presented as means (standard deviations), medians
(interquartile ranges [IQR]), and percentages. The Shapiro-
Wilk test was used to determine the normality of data
distribution. Diﬀerences between groups were analyzed
with the Mann-Whitney (continuous non parametric data)
or the Chi-square test (percentages). Changes after each
treatment phase within studied groups were assessed using
the Wilcoxon rank test. A P value < 0.05 was considered as
statistically signiﬁcant. Sample size calculation was primarily
based on the assumption that hot ﬂush frequency would
be reduced 50% in the RCE group (15% in the placebo
group). Hence, a sample size of 49 individuals per group was
calculated in order to achieve an 80% power at a two-sided
alpha level of 0.05.
3. Results
During the study period, a total of 113 women consented
to participate. Fifty-three were randomized to group A and
sixty to group B. Four women started HT and were excluded.
Thus, data of 109 women who completed treatment (Group
A: 50 and Group B: 59) was used for analysis. No signiﬁcant
diﬀerences were observed between study groups regarding
basal characteristics (Table 1). Hysterectomy was in all cases
due to a benign cause (i.e., uterine ﬁbroids), and former
HT users had stopped intake at least 6 months prior to
recruitment with a maximum previous intake of 7.5 years.
No side eﬀects were encountered after treatment with the
active compound or the placebo group.
W o m e ni nb o t hs t u d i e dg r o u p sr e p o r t e dah i g h e rV A S
subjective percent improvement of scalp hair and skin status,
libido, mood, sleep, and tiredness after RCE intervention as
comparedtoplacebo.Ingeneral,reportedimprovementover
urinary complaints, nail, body hair, and mucosa (oral, nasal,
and ocular) status did not diﬀer between treatment phases
(intra- and intergroup). Women in both groups reportedObstetrics and Gynecology International 3
Table 1: Demographic data of studied women at baseline∗.
All (n = 109) Group A (n = 50) Group B (n = 59)
Age (years) 53.5 ± 7.1 54.5 ± 6.2 53.7 ± 7.8
BMI (Kg/m2) 24.7 ± 3.9 24.5 ± 3.9 24.9 ± 3.9
Hysterectomy (%) 17 (15.6) 9 (18.0) 8 (13.6)
Former HT use (%) 64 (58.7) 29 (58.0) 35 (59.3)
∗Data are presented as mean ± standard deviations or percentages (n,% ) ;B M I :b o d ym a s si n d e x ;H T :h o r m o n et h e r a p y ;G r o u pA :R C E ;G r o u pB :p l a c e b o .
Table 2: Subjective symptom or condition improvement after treatment as assessed with the VAS.
Studied parameters
Group A Group B
After RCE After placebo After placebo After RCE
Scalp hair (better texture, less fragility,
and overall condition)
7.3 ± 16.6†
[0, 0]
4.2 ± 13.9
[0, 0]
0.2 ± 0.9
[0, 0]
6.3 ± 13.9∗
[0, 0]
Body hair (less growth) 6.4 ± 16.5
[0, 0]
2.6 ± 10.9∗
[0, 0]
1.0 ± 3.4
[0, 0]
2.2 ± 6.2
[0, 0]
Skin condition (better texture, more
moisture, and better overall condition)
18.6 ± 20.5†
[15, 32]
6.2 ± 16.2∗
[0, 0]
5.0 ± 11.0
[0, 5]
17.7 ± 21.2∗†
[5, 35.0]
Ocular complaint (dryness and
burning)
7.8 ± 18.0†
[0, 7]
5.3 ± 15.1
[0, 0]
2.2 ± 9.5
[0, 0]
6.0 ± 13.7
[0, 1.3]
Oral mucosa complaint (dryness and
burning)
3.9 ± 14.0
[0, 0]
3.3 ± 13.0
[0, 0]
1.8 ± 5.2
[0, 0]
2.8 ± 9.7
[0, 0]
Nasal mucosa complaint (dryness and
ﬁssuring)
4.2 ± 15.3
[0, 0]
2.6 ± 9.1
[0, 0]
1.6 ± 5.3
[0, 0]
6.2 ± 16.1∗
[0, 1.3]
Nails condition (change in thickness
and stability)
5.6 ± 16.2
[0, 0]
6.2 ± 16.7
[0, 0]
3.3 ± 10.0
[0, 1.3]
10.8 ± 19.3∗
[0, 11.3]
Digestive complaints (diarrhea and
constipation)
6.0 ± 16.1†
[0, 0]
14.4 ± 19.4∗
[0, 32.0]
19.5 ± 26.0
[6, 31.3]
11.9 ± 26.4∗
[0, 10.8]
Libido 18.0 ± 16.7†
[17, 30]
4.9 ± 14.3∗
[0, 0]
5.0 ± 12.4
[0, 1.3]
17.8 ± 20.9∗†
[10, 30]
Urinary complaint (incontinence and
dysuria)
5.2 ± 18.1
[0, 0]
5.4 ± 17.3
[0, 0]
3.0 ± 13.7
[0, 0]
4.7 ± 15.0
[0, 0]
Mood complaint 68.5 ± 33.6†
[80, 48]
15.0 ± 25.2∗
[0, 25.3]
7.7 ± 19.2
[0, 0.8]
65.8 ± 37.8∗†
[78.5, 70.5]
Sleeping complaint 73.5 ± 33.4†
[90, 45]
16.2 ± 25.7∗
[0, 25]
9.8 ± 23.0
[0, 7]
70.6 ± 3.5∗†
[81.5, 62.2]
Tiredness 61.7 ± 45.8†
[96, 100]
16.1 ± 24.5∗
[0, 26.3]
8.3 ± 22.7
[0, 0]
56.1 ± 47.7∗†
[92.0, 100]
Overall satisfaction with treatment 87.3 ± 26.6†
[100, 12.5]
29.8 ± 31.4∗
[30, 50]
14.7 ± 26.8
[0, 19]
81.7 ± 26.8∗†
[100, 43.7]
Values are expressed as percent improvement and presented as mean ± standard deviations [median, interquartile range]; ∗P<0.05 when comparing phases
in same group using Wilcoxon rank test; †P<0.05 as compared to placebo phase of the contrary group using the Mann-Whitney test.
higher subjective improvement of digestive complaints after
placebo. Overall satisfaction with treatment was reported
higher after RCE intervention in both assigned groups as
compared to placebo (Table 2).
4. Discussion
In the past decade, there has been an increasing trend toward
individualizing treatment options for the menopause with a
interesting focus on alternatives to estrogens [23–25]. This
situation has occurred due to risk-beneﬁt issues raised after
the publication of the WHI results [23]. Tendency seems to
be more pronounced among those with contraindications
or with high-risk situations. Among available alternative
treatments, one can mention phytoestrogens, plant-derived
molecules, mainly represented by isoﬂavones, that dis-
play estrogenic like eﬀects [26–28]. Although less potent
than conventional estrogenic compounds, their selective
beta-estrogenic receptor-binding properties allow beneﬁcial
eﬀects on speciﬁc organs or systems [28]. Interest in red
clover isoﬂavones (a kind of phytoestrogen) has equally
grown among physicians and women with reports evidenc-
ing positive eﬀects over menopausal symptoms [20, 29],
vaginal health [21], serum lipids [30], and a promising
safety proﬁle [1]. However, to date, few or no studies using
isoﬂavones have reported eﬀects on skin, appendages, and
mucosal status.4 Obstetrics and Gynecology International
Compared to the eﬀect of estrogens on hair thickness
or loss, eﬀects on growth have been poorly investigated
[31]. Estrogens seem to prolong the anagen cycle of the
hair follicle [32]. Although hair follicle is an ER2 (beta)
target [33], growth could predominantly be regulated by the
insulin like growth factor 1 (IGF-1) [34] through crosstalk
with the ER1 (alpha) [35]. A recently published mouse
model trial showed isoﬂavone-induced IGF-1 increase in
hair follicle dermal papilla cells, and thereby increased hair
growth [36]. The present study found that women reported
better subjective improvement of scalp hair and skin status
after RCE intervention as compared to placebo. Reported
improvement of nail, body hair (less growth), or mucosal
statusdidnotstatisticallydiﬀeramongstudiedphases(intra-
and intergroup). Regarding the latter, important to mention
is that although the pathophysiology of the menopausal
“burning mouth syndrome” is still unclear [37], HT use
may improve this condition [38–41]. Although a Finnish
group detected ER2 as the predominant estrogenic receptor
in oral mucosa and salivary gland, they also pointed out that
there are many other potent regulatory mechanisms possibly
involved in the regulation of mucosal status [41]. Nasal
mucosa expresses ER2 yet no ER1 or progesterone receptor
(PR). ER2 count decreases with age (men and women) at
this site and seems directly associated to quality of life [42].
Womenof our series reported no subjectiveimprovement on
nasal mucosal status (dryness and ﬁssuring).
In the present study, women of both groups reported
better subjective improvement of skin condition (better
texture, moisture, and overall condition) after RCE phase
as compared to placebo. ER1 and ER2 have been shown
in certain skin layers but expressed diﬀerently according to
the skin region. Lower risk for malignant skin changes in
women is partly due to the higher estrogen status than in
men [43]. It has been reported that HT clinically improves
skin elasticity, thickness, and hydration [44]a n dr e d u c e s
shrinks [45]. Surprisingly, our results seem to favor the fact
that not only ER1 yet also ER2 can be expressed in the
epidermis of diﬀerent anatomical sites [31]. Despite this,
we must bear in mind isoﬂavones’ SERM proﬁle displaying
also anti-inﬂammatory [46], UV protective [47], and wound
healing [48] potentials.
No subjective improvement over urinary complaints
were found in our study despite the fact that isoﬂavones have
shown positive eﬀects on the urethral sphincter mechanism
in the animal model [49] and in patients with prostate
carcinoma [50]. The latter clinical study [50], however, used
a rather high isoﬂavone dose (200mg/day for 6 months).
This dosage and duration are still uncommon in clinical
menopausal isoﬂavone trials.
Better subject improvement of libido, mood, sleep, and
tiredness was also evident in the present series after RCE
supplementation as compared to placebo (both groups).
Chedraui et al. [21] and Hidalgo et al. [20]h a v ed e m o n -
strated improvement of libido and vaginal complaints after
RCE treatment. Contrarily, del Giorno [51] could not ﬁnd
libido improvement after using 40mg/day RCE dose which
is lower than that used in our trial. We have previously
reported that RCE supplementation improved anxiety and
depressive symptoms in postmenopausal women [19] ,af a c t
that supports our present data.
Finally, the authors acknowledge the limitations of
analyzing subjective data obtained with a VAS and the lack
of VAS-baseline values for the studied parameters in order
to perform comparisons. However, VAS baseline assessment
was not carried due to the fact that many women could not
recall exactly when complaints started. Despite this, to date,
the eﬀect of RCE on skin, appendages and, mucosal status
has not been reported, and this may be seen as a potential
added value of the present study. However, more research
is required in order to support our preliminary ﬁndings on
these aspects.
In conclusion, RCE supplementation exerted a subject
improvement of scalp hair and skin status as well as libido,
mood, sleep, and tiredness in postmenopausal women.
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